Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.7%

4 terminated/withdrawn out of 46 trials

Success Rate

86.7%

+0.2% vs industry average

Late-Stage Pipeline

15%

7 trials in Phase 3/4

Results Transparency

104%

27 of 26 completed trials have results

Key Signals

27 with results

Enrollment Performance

Analytics

Phase 1
24(52.2%)
Phase 2
15(32.6%)
Phase 3
7(15.2%)
46Total
Phase 1(24)
Phase 2(15)
Phase 3(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (46)

Showing 20 of 46 trials
NCT02029443Phase 1Active Not Recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Role: lead

NCT03623373Phase 2Completed

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Role: collaborator

NCT02717624Phase 1Active Not Recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Role: lead

NCT03328273Phase 1Active Not Recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Role: lead

NCT04529772Phase 3Active Not Recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Role: lead

NCT02477696Phase 3Active Not Recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Role: lead

NCT02717611Phase 2Active Not Recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Role: lead

NCT02586857Phase 1Active Not Recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Role: lead

NCT02180724Phase 2Active Not Recruiting

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Role: lead

NCT02972840Phase 3Active Not Recruiting

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Role: lead

NCT02213926Phase 2Active Not Recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Role: lead

NCT02970318Phase 3Active Not Recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Role: lead

NCT02337829Phase 2Completed

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Role: lead

NCT02296918Phase 1Completed

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Role: lead

NCT02362035Phase 1Completed

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Role: lead

NCT02328014Phase 1Completed

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Role: lead

NCT02180711Phase 1Active Not Recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Role: lead

NCT02475681Phase 3Active Not Recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Role: lead

NCT02157324Phase 1Active Not Recruiting

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Role: lead

NCT03836261Phase 3Active Not Recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Role: lead